News from mast therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 12, 2015, 16:05 ET
Mast Therapeutics, Inc. logo

Mast Therapeutics Reports Second Quarter 2015 Financial Results

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology...

Aug 06, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics To Host Second Quarter 2015 Financial Results And Corporate Update Conference Call

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology...

May 28, 2015, 16:30 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics Announces Change In Board Of Directors

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology...

May 26, 2015, 08:00 ET
Mast Therapeutics, Inc. logo

Mast Therapeutics Announces Initiation Of EPIC-E Study

Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology...

May 11, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics Reports First Quarter 2015 Financial Results

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology...

Apr 21, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark

Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology...

Apr 09, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast To Present New Data Supporting Vepoloxamer (MST-188) In Sickle Cell Disease At 9th Annual Sickle Cell Disease Research And Education Symposium And 38th National Sickle Cell Disease Scientific Meeting

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology...

Mar 24, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology...

Mar 23, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast To Develop Vepoloxamer (MST-188) In Chronic Heart Failure

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology...

Mar 02, 2015, 08:00 ET
Mast Therapeutics, Inc. logo

Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced preliminary findings from a randomized,...

Feb 24, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics To Present At Cowen And Company's 35th Annual Healthcare Conference On March 2nd

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company's Chief Executive...

Feb 11, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics Announces New Data Supporting Vepoloxamer In Embolic Stroke

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that, in a model of embolic stroke with...

Feb 04, 2015, 08:00 ET
Mast Therapeutics, Inc. logo

Mast Therapeutics Announces Initiation Of Phase 2a Studies Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported the initiation of patient dosing in two institutional-sponsored Phase 2a studies of...

Feb 03, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics To Present At 17th Annual BIO CEO & Investor Conference On February 9th

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company's Chief Executive...

Jan 24, 2015, 19:30 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics Announces Management Change

Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced a management change in connection with...

Jan 07, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics To Present At 2015 Biotech Showcase Conference On January 12th

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company's Chief Executive...

Jan 05, 2015, 17:17 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics Provides Update On Epic Study Enrollment And 2015 Milestones

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today reported that enrollment in its pivotal EPIC study...

Dec 30, 2014, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics To Host Corporate Conference Call

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that it will hold a conference call at...

Dec 09, 2014, 08:00 ET
Mast Therapeutics, Inc. logo

Mast Announces Plans For Development Of Vepoloxamer (MST-188) In Heart Failure

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today provided details of its plan to develop...

Nov 26, 2014, 08:00 ET
Mast Therapeutics, Inc. logo

Mast Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference On December 3rd

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company's Chief Executive...